The changes of gene expression profiles in hydatidiform mole and choriocarcinoma with hyperplasia of trophoblasts

International Journal of Gynecological Cancer

Volumn 14, Issue 5, 2004, Pages 984-997

  Cui, J Q ^a   Shi, Yi Fu ^a,b   Zhou, H J ^a   Li, J Q ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NONE   (China)

Author keywords

Choriocarcinoma; Differential expression; DNA microarray; Gene; Gene expression profiles; Hydatidiform mole

Indexed keywords

RIBONUCLEOTIDE REDUCTASE; THYMIDINE KINASE;

ARTICLE; CELL PROLIFERATION; CHORIOCARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TROPHOBLASTIC TUMOR; UNINDEXED SEQUENCE; UPREGULATION;

ADULT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHORIOCARCINOMA; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREGNANCY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UTERINE NEOPLASMS;

EID: 4544363241     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.14539.x     Document Type: Article

References (49)

1. Tanaka TS, Kunath T, Kimber W et al. Gene expression profiling of embryo-derived stem cells reveals candidate genes associated with pluripotency and lineage specificity. Genome Res 2002;12:1921-8.
2. Bilban M, Head S, Desovye G, Quaranta V. DNA microarrays: a novel approach to investigate genomics in trophoblast invasion. Placenta 2000;21(Suppl. A):S99-105.
3. Aronow BJ, Richardson BD, Handwerger S. Microarray analysis of trophoblast differentiation: gene expression reprogramming in key gene function categories. Physiol Genomics 2001;6:105-16.
4. Handwerger S, Aronow B. Dynamic changes in gene expression during human trophoblast differentiation. Recent Prog Harm Res 2003;58:263-81.
5. Galaviz-Hernandez C, Stagg C, de Ridder G et al. Plac8 and Plac9, novel placental-enriched genes identified through microarray analysis. Gene 2003;309:81-9.
6. Kim SJ, Park SE, Lee C et al. Altered imprinting, promoter usage, and expression of insulin-like growth factor-II gene in gestational trophoblastic diseases. Gynecol Oncol 2003;88:411-8.
7. Fisher RA, Hodges MD. Genomic imprinting in gestational trophoblastic disease - a review. Placenta 2003;24(Suppl. A):S111-8.
8. Jun SY, Ro JY, Kim KR. p57kip2 is useful in the classification and differential diagnosis of complete and partial hydatidiform moles. Histopathology 2003;43:17-25.
9. Yang X, Zhang Z, Jia C, Li J, Yin L, Jiang S. The relationship between expression of c-ras, c-erbB-2, nm23, and p53 gene products and development of trophoblastic tumor and their predictive significance for the malignant transformation of complete hydatidiform mole. Gynecol Oncol 2002;85:438-44.
10. Tuncer ZS, Vegh GL, Fulop V, Genest DR, Mok SC, Berkowitz RS. Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor. Gynecol Oncol 2000;77:389-93.
11. Fulop V, Mok SC, Genest DR, Gati I, Doszpod J, Berkowitz RS. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 1998;43:119-27.
12. Amezcua CA, Bahador A, Naidu YM, Felix JC. Expression of human telomerase reverse transcriptase, the catalytic subunit of telomerase, is associated with the development of persistent disease in complete hydatidiform moles. Am J Obstet Gynecol 2001;184:1441-6.
13. Chen RJ, Chu CT, Huang SC, Chow SN, Hsieh CY. Telomerase activity in gestational trophoblastic disease and placental tissue from early and late human pregnancies. Hum Reprod 2002,17:463-8.
14. Nishi H, Yahata N, Ohyashiki K et al. Comparison of telomerase activity in normal chorionic villi to trophoblastic diseases. Int J Oncol 1998;12:81-5.
15. Bamberger AM, Sudani S, Wagener C, Loning T. Expression pattern of the adhesion molecule CEACAM1 (C-CAM,CD66a, BGP) in gestational trophoblastic lesions. Int J Gynecol Pathol 2001;20:160-5.
16. Li HW, Cheung AN, Tsao SW, Cheung AL, O WS. Expression of e-cadherin and beta-catenin in trophoblastic tissue in normal and pathological pregnancies. Int J Gynecol Pathol 2003;22:63-70.
17. Bowen JM, Chamley L, Mitchell MD, Keelan JA. Cytokines of the placenta and extra-placental membranes: biosynthesis, secretion and roles in establishment of pregnancy in women. Placenta 2002;23:239-56.
18. Okamoto T, Niu R, Yamada S, Osawa M. Reduced expression of tissue inhibitor of metalloproteinase (TIMP)-2 in gestational trophoblastic diseases. Mol Hum Reprod 2002;8:392-8.
19. Vegh GL, Selcuk Tuncer Z, Fulop V, Genest DR, Mok SC, Berkowitz RS. Matrix metalloproteinases and their inhibitors in gestational trophoblastic diseases and normal placenta. Gynecol Oncol 1999;75:248-53.
20. Bae SN, Kim SJ. Telomerase activity in complete hydatidiform mole. Am J Obstet Gynecol 1999;180:328-33.
21. Clarke PA, te Poele R, Wooster R, Workman P. Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol 2001;62:1311-36.
22. Williams NS, Gaynor RB, Scoggin S et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003;9:931-46.
23. Dooley TP, Reddy SP, Wilborn TW, Davis RL. Biomarkers of human cutaneous squamous cell carcinoma from tissues and cell lines identified by DNA microarrays and qRT-PCR. Biochem Biophys Res Commun 2003;306:1026-36.
24. Vegh GL, Fulop V, Liu Y et al. Differential gene expression pattern between normal human trophoblast and choriocarcinoma cell lines: downregulation of heat shock protein-27 in choriocarcinoma in vitro and in vivo. Gynecol Oncol 1999;75:391-6.
25. Kato HD, Terao Y, Ogawa M et al. Growth-associated gene expression profiles by microarray analysis of trophoblast of molar pregnancies and normal villi. Int J Gynecol Pathol 2002;21:255-60.
26. Kliman HJ, Nestler JE, Sermasi E, Sanger JM, Strauss JF 3rd. Purification, characterization, and in vitro differentiation of cytotrophoblasts from human term placentae. Endocrinology 1986;118:1567-82.
27. Yao Li, Yali Li, Tang R et al. Discovery and analysis of hepatocellular carcinoma genes using cDNA microarrays. J Cancer Res Clin Oncol 2002;128:369-79.
28. Mader RM, Sieder AE, Braun J et al. Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro. Biochem Pharmacol 1997;54:1233-42.
29. Fulop V, Mok SC, Gati I, Berkowitz RS. Recent advances in molecular biology of gestational trophoblastic diseases. A review. J Reprod Med 2002;47:369-79.
30. Pusch O, Soucek T, Hengstschlager-Ottnad E, Bernaschek G, Hengstschlager M. Cellular targets for activation by c-Myc include the DNA metabolism enzyme thymidine kinase. DNA Cell Biol 1997;16:737-47.
31. Foekens JA, Romain S, Look MP, Martin PM, Klijn JG. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 2001;61:1421-5.
32. Chung YM, Park S, Park JK, Kim Y, Kang Y, Yoo YD. Establishment and characterization of 5-fluorouracil-resistantgastric cancer cells. Cancer Lett 2000;159:95-101.
33. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nakao M, Miki T. Significance of thymidine kinase activity in renal cell carcinoma. J Urol 2003;169:706-9.
34. Mao Y, Wu J, Wang N, Wu C, He Q, Skog S. A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Invest 2002;20:922-31.
35. Fujiwaki R, Hata K, Nakayama K et al. Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes. Int J Cancer 2002;99:328-35.
36. Derenzini M, Montanaro L, Chilla A et al. Evaluation of thymidylate synthase protein expression by Western blotting and immunohistochemistry on human colon carcinoma xenografts in nude mice. J Histochem Cytochem 2002;50:1633-40.
37. Edler D, Hallstrom M, Ragnhammar P, Blomgren H. Thymidylate synthase expression in rectal cancer and proliferation, assessed by cyclin A and Ki-67 expression. Anticancer Res 2002;22:3113-6.
38. Nakagawa T, Otake Y, Yanagihara K et al. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer 2004;43:145-9.
39. Shintani Y, Ohta M, Hirabayashi H et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003;104:790-5.
40. Ichikawa W, Uetake H, Shirota Y et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003;9:786-91.
41. Gonen M, Hummer A, Zervoudakis A et al. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 2003;21:406-12.
42. Burton TR, Kashour T, Wright JA, Amara FM. Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy. Int J Oncol 2003;22:21-31.
43. Zhou BS, Tsai P, Ker R et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 1998;16:43-9.
44. Fan H, Villegas C, Huang A, Wright JA. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 1998;58:1650-3.
45. Jung CP, Motwani MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001;7:2527-36.
46. Chen S, Zhou B, He F, Yen Y. Inhibition of human cancer cell growth by inducible expression of human ribonucleotide reductase antisense cDNA. Antisense Nucleic Acid Drug Dev 2000;10:111-6.
47. Lee Y, Vassilakos A, Feng N et al. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 2003;63:2802-11.
48. Jensen RA, Page DL, Holt JT. Identification of genes expressed in premalignant breast disease by microscopy-directed cloning. Proc Natl Acad Sci USA 1994;91:9257-61.
49. Okamura H, Kamei T, Sakuma N, Hanai N, Ishihara T. Ribonucleotide reductase immunoreactivity in adenocarcinoma cells and malignant or reactive mesothelial cells in serous effusions. Acta Cytol 2003;47:209-15.